Kilickap, S. Et Al. 2019. Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey. JOURNAL OF THORACIC ONCOLOGY , no.10 .

Kilickap, S., Demirci, U., Bugdayci, F., Tural, D., KORKMAZ, T., PAYDAŞ, S., ... Yilmaz, C.(2019). Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey. JOURNAL OF THORACIC ONCOLOGY , no.10.

Kilickap, S. Et Al. "Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey," JOURNAL OF THORACIC ONCOLOGY , no.10, 2019

Kilickap, S. Et Al. "Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey." JOURNAL OF THORACIC ONCOLOGY , no.10, 2019

Kilickap, S. Et Al. (2019) . "Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey." JOURNAL OF THORACIC ONCOLOGY , no.10.

@article{article, author={S. Kilickap Et Al. }, title={Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey}, journal={JOURNAL OF THORACIC ONCOLOGY}, year=2019}